Assenagon Asset Management S.A. Sells 38,271 Shares of STAAR Surgical (NASDAQ:STAA)

Assenagon Asset Management S.A. lessened its position in STAAR Surgical (NASDAQ:STAA) by 42.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,163 shares of the medical instruments supplier’s stock after selling 38,271 shares during the period. Assenagon Asset Management S.A. owned about 0.11% of STAAR Surgical worth $1,267,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock worth $43,641,000 after purchasing an additional 31,212 shares during the period. Mutual of America Capital Management LLC boosted its stake in shares of STAAR Surgical by 214.7% during the 2nd quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock worth $1,260,000 after acquiring an additional 18,051 shares during the period. HighTower Advisors LLC acquired a new position in shares of STAAR Surgical during the 3rd quarter worth approximately $336,000. Algert Global LLC raised its stake in STAAR Surgical by 13.5% in the 2nd quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier’s stock valued at $5,554,000 after acquiring an additional 13,901 shares during the period. Finally, Polar Asset Management Partners Inc. lifted its holdings in STAAR Surgical by 44.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier’s stock valued at $6,271,000 after purchasing an additional 51,800 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

STAA has been the topic of several research reports. Stephens upgraded shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group cut their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $42.83.

STAAR Surgical Stock Up 3.8 %

NASDAQ STAA opened at $23.95 on Friday. The firm has a 50-day moving average price of $24.92 and a two-hundred day moving average price of $31.34. STAAR Surgical has a 12-month low of $21.13 and a 12-month high of $52.68. The company has a market capitalization of $1.18 billion, a P/E ratio of 54.43 and a beta of 0.63.

Insider Activity

In related news, major shareholder Broadwood Partners, L.P. purchased 23,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The shares were bought at an average price of $24.33 per share, for a total transaction of $559,590.00. Following the completion of the transaction, the insider now owns 10,848,631 shares of the company’s stock, valued at approximately $263,947,192.23. This trade represents a 0.21 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Over the last ninety days, insiders acquired 105,876 shares of company stock worth $2,487,168. Corporate insiders own 1.00% of the company’s stock.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.